10.9. Analysis.

Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 9 Immune system: allergic reactions.

Immune system: allergic reactions
Study
Confino‐Cohen 2005	A case report of pruritic maculopapular skin rash developing during MPH treatment. The rash improved with antihistamines and re‐challenge at a lower dose caused the reappearance, though less severe, of the rash. Desensitisation through graded exposure of MPH in incremental doses prevented further rash development
Vashi 2011	After 8 months of using an MPH patch the patient presented with pruritic dermatitis. She had itchy, burning, red lesions. Symptoms began on her hip at the area of patch placement, then progressively spread to her arms, legs, abdomen, and back. MPH discontinued: Symptoms lasted for 2 months. First and second patch test. Re‐tested with MPH patch: Nine days after the first test the patient presented with recall reaction, characterized by a return of the original pruritic dermatitis to her entire back, similar to the eruption that had occurred months previously after therapeutical use of MPH patch. Avoidance of MPH patches: symptom‐free